An independent intelligence board aggregating credible research, preprints, clinical findings, biohacking experiments, and community discussions on therapeutic peptides, longevity science, and evidence-based anti-aging. Stories are scored for relevance, credibility, novelty, momentum, and practicality so the most important findings surface first.
Ascletis, a drug company, announced it will present study results at the ObesityWeek 2026 meeting about two experimental medicines aimed at weight loss and metabolism. One is ASC48, a pill that targets the GIP receptor. The other is ASC37, a three-way peptide (a short protein-like molecule) that activates GLP-1, GIP and glucagon receptors. The announcement says results will be shown at the conference, but the snippet doesn’t include the data itself or detailed outcomes. To make sense of the names: ASC48 is described as an oral small-molecule GIPR agonist. That means it’s a pill designed to mimic a natural hormone called GIP (glucose-dependent insulinotropic polypeptide) and turn on the GIP receptor (GIPR). ASC37 is a peptide drug that acts on three receptors — GLP-1, GIP and the glucagon receptor (GCGR) — all of which influence appetite, blood sugar and energy use. In plain terms, ASC48 is a chemical that aims to trick the body into responding as if it had more of a certain gut hormone, and ASC37 is a short-protein drug meant to trigger three different appetite/metabolism switches at once. The announcement only says Ascletis will present study results; it doesn’t specify whether the studies were in people or animals, how many participants there were, or how big any effects were. That’s important: early company press releases often precede more detailed data, which could range from preliminary lab results to full human trials. Until the conference presentation is available, we don’t know whether these drugs led to meaningful weight loss, improved blood sugar, or what side effects appeared. So take the headline as a sign of progress and interest, not proof the drugs work in people yet. Why this matters is straightforward. Drugs that target GLP-1, GIP and glucagon pathways are currently the hottest area in obesity and diabetes treatment because existing medicines that hit GLP-1 alone (like semaglutide, known as Ozempic or Wegovy) have shown large weight-loss effects. A pill that works on GIP could offer an easier, non-injectable option. A triple-agonist peptide could also increase effectiveness by combining mechanisms, possibly giving more weight loss or better blood sugar control. If these molecules are safe and effective in humans, they could expand options for people struggling with obesity or metabolic disease. But there are important caveats and risks. The snippet doesn’t state regulatory status, so these are experimental drugs and not approved therapies. Peptide drugs are often injectable, so an oral peptide would be notable; ASC48 being a small molecule pill is easier to take, but small molecules can have different side effects. Triple agonists can increase efficacy but also raise safety questions, like heart effects, nausea, or other hormone-related problems. We don’t know long-term effects or who should avoid them. Until full trial data are published and reviewed by regulators, doctors won’t be able to recommend these to patients. Bottom line: Ascletis will present results on two experimental weight/metabolism drugs at ObesityWeek, which is a development to watch — but the actual benefits and risks won’t be clear until the detailed data are released and peer-reviewed.
Source: Macau Business